Two of Roche’s oncology blockbusters are facing dire straits with biosims on the march. Now, a major insurer and PBM is betting on the new guys.
UnitedHealthcare is making demands about pharma's new strategy to lower prices, an analyst wrote.
After an Optum higher-up left for Amazon's new healthcare partnership, Optum sued the former executive for trade secrets theft.
Thanks to groundwork laid by the feds, UnitedHealthcare is suing dozens of generics companies for alleged price fixing—and it wants its money back.
As J&J vies with biosims to big-selling Remicade, prices across the category are falling, an analyst says—and Pfizer's Inflectra has tumbled the most.
UnitedHealthcare unveiled a new program to reward patients for choosing a cheaper HIV treatment option, scaring Gilead Sciences investors days later.
After a CMS rule change in August, UnitedHealthcare is introducing step therapy in Medicare Advantage plans to favor biosimilars over certain brands.
Amazon's plan to jump into drug sales has hit a snag, and the retail giant has reportedly put at least one plan on ice.
J&J paid out $15 billion in rebates and discounts in 2017 as its average selling price slipped 4.6%.
In the wake of the Aetna-CVS combo, Cigna's Express Scripts buy could mean more pricing resistance ahead for drugmakers.